Table 1 Selected antibody–drug conjugates in Phase II or III trials ... So, we have developed conditionally labile peptide bonds that are stable in the circulation. The peptides are not ...

Antibody–drug conjugates have emerged as a powerful tool ... The drug linker is typically created as a peptide or carbohydrate that is cleaved inside the tumour cell after internalization ...

研究结果表明，这种方法在多个方面都是有效的，其不仅能激活人类血液样本中正确类型的免疫细胞，还通过对动物模型进行研究发现，接受这种治疗的小鼠的生存期延长了，而且在更高的剂量下也能使得小鼠免于癌症影响，而且这种方法要比研究人员此前研究的癌症疗法更加安全。

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in ...

Reference: Mebrahtu A, Laurén I, Veerman R, et al. A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in ...

antibody-oligonucleotide conjugates, peptide-drug conjugates plus many other novel conjugates types. This event serves as the ultimate hotbed of discussion and potential partnerships for 100 ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...